Special Healthcare Services for Pediatrics: Community & School-Based Services

1. Overview and Definition

• Maternal health
• Family planning
• Child health
• School health
• Handicapped/disabled children
• Care of children in special settings (day care centres, etc.)

2. Principles of Modern MCH / Pediatric Community Services

Integration of Care

Risk Approach

Flexibility and Community Adaptation

3. School Health Services (Core Pediatric Community Service)

Essential School Health Services

Desirable (Health Promoting Schools)

• Counselling services
• Regular yoga, physical education, and health education
• Peer leaders as health educators
• Adolescent health education
• Linkages with out-of-school children
• Health clubs and health cabinets
• First aid room / corners / clinics

4. School Health Programme Under Ayushman Bharat

Activity Schedule

Age-Appropriate Health Promotion

• Health, growth, and development
• Personal safety
• Nutrition and physical activity
• Hygiene practices
• Prevention of malaria, dengue, TB, worm infestation, diarrhoea, and vaccine-preventable diseases

• Puberty and related changes
• Eye care, oral hygiene
• Nutrition
• Bullying prevention
• Meditation and yoga
• Internet safety and media literacy
• Prevention of substance abuse
• HIV/AIDS and mental health

5. Adolescent Health Care (School-Linked)

• Reproductive health information, counselling, and services (pregnancy, contraception, menstrual problems)
• Tetanus immunization
• Nutritional counselling and prevention of nutritional anaemia
• STI/HIV/RTI management
• Referral for VCTC and PPTCT services

6. Children with Special Health Care Needs (CYSHCN) - Emergency and Specialist Perspective

• Although specialty care is often at pediatric EDs affiliated with tertiary children's hospitals, a greater number of complex pediatric patients are cared for in general EDs, due to proximity and access. General EDs must be prepared for this.
• Emergency Information Forms (EIFs) summarize chronic conditions, medications, devices, and treatment plans for CYSHCN. These allow rapid stabilization until detailed records are obtained. Specialists should provide EIFs for complex patients.
• Children with autism spectrum disorder or sensory processing disorders need special adjustments in loud/unpredictable environments like EDs - staff should ask about sensory sensitivities (touch, noise, lighting) to guide evaluation.
• Caregivers (parents, daily caregivers) are key sources of baseline information on behavior and mental status - their input must be sought.

7. School-Based Health Centers (SBHCs) - International Model

• Pediatric primary care (medical home for students without one)
• Mental health services
• Subspecialty referrals
• On-site management of chronic conditions (e.g., asthma)
• Outreach-based programs (mobile dental vans, nutrition education, group therapy)

8. Care Coordination and System Support for CYSHCN

Summary Table: Levels of Special Pediatric Healthcare Services

Pharmaceutical Care for Pediatrics

1. Why Pediatrics Requires Specialized Pharmaceutical Care

• Dose is usually expressed as mg/kg body weight up to the maximum adult dose
• For narrow therapeutic index drugs (e.g., oncology agents, digoxin), mg/m² body surface area is preferred
• BSA calculations are prone to measurement error in infants - caution required
• PK parameters must be recalibrated for each age group: neonate, infant, toddler, school-age child, adolescent

2. Pediatric Age Classifications

3. Developmental Pharmacokinetics (ADME in Children)

A. Absorption

• Gastric pH is higher (less acidic) in neonates - acid-labile drugs (e.g., penicillin G) have higher bioavailability; acid-dependent drugs have lower bioavailability
• Gastric emptying is slower and irregular in neonates - delays time to peak plasma concentration
• Passive and active intestinal transport are fully mature by approximately 4 months of age
• First-pass metabolism is reduced in neonates (immature CYP enzymes) - bioavailability of some oral drugs is higher than in adults

• Neonates and infants have a thinner stratum corneum and higher body surface area-to-weight ratio - significantly greater systemic absorption of topically applied drugs (including ophthalmic drops, steroid creams)

• Used when oral/IV routes are unavailable; adult suppositories are sometimes cut, but accuracy and stability are not guaranteed

• Ocular drug volume is smaller in infants; tear volume is reduced in neonates (2.5 µL in neonates vs. 6 µL in adults) - topically applied drugs become more concentrated in younger patients
• Drugs absorbed via nasolacrimal duct bypass first-pass metabolism - infants at greater risk of systemic side effects (especially with immature blood-brain barrier and reduced hepatic clearance)
• A newborn requires only ½ the adult eye-drop dose to achieve equivalent ocular concentration; ⅔ at age 3; 90% at age 6

B. Distribution

• Body water content is markedly higher in neonates (~80% total body water) compared to adults (~60%) - water-soluble drugs have a larger volume of distribution, requiring higher mg/kg loading doses
• Body fat content is lower in premature neonates - lipophilic drug distribution is reduced
• Plasma protein binding is lower in neonates - less albumin, lower binding affinity, elevated free fatty acids and bilirubin competing for binding sites - more free (active/toxic) drug in circulation
• Blood-brain barrier is immature in neonates - CNS drugs (and inadvertent CNS toxins) penetrate more readily

C. Metabolism

• Hepatic CYP enzyme systems (CYP1A2, CYP2D6, CYP3A4, etc.) are immature at birth and mature at different rates:
  • CYP3A7 (fetal isoform) is active at birth, then declines
  • CYP3A4, CYP2D6, CYP1A2 gradually increase - adult levels reached between months to years
• Phase II conjugation (glucuronidation) is also immature in neonates - this was the basis for "grey baby syndrome" with chloramphenicol (inability to glucuronidate → toxic accumulation)
• Digoxin inactivation in the gut lumen increases with age: 1-3% in infants → 7% in school-age children → 10% in adolescents → 40% in adults - this is why digoxin loading doses are higher on a µg/kg basis in younger children (45 µg/kg in infants vs. 25 µg/kg in school-age children)

D. Excretion (Renal)

• Glomerular filtration rate (GFR) at birth is ~2-4 mL/min; reaches adult levels by 6-12 months
• Tubular secretion and reabsorption mature more slowly - renally cleared drugs (aminoglycosides, penicillins, vancomycin) accumulate in neonates
• Dose intervals must be extended for renally cleared drugs in neonates
• As GFR matures rapidly in infancy, dosing intervals need frequent re-evaluation

4. Pediatric Drug Formulations

1. Produce minimal lifestyle impact (lowest dosing frequency, palatable)
2. Allow individualized or dose-banded dosing
3. Ensure sufficient bioavailability
4. Use non-toxic excipients (e.g., sorbitol, propylene glycol, benzyl alcohol are hazardous in neonates)
5. Be convenient and reliable to administer
6. Have a robust, affordable production process

Formulation Types by Route

Historical warning: In 1938, 107 children died from kidney failure due to diethylene glycol used as an excipient in sulfanilamide. Excipient safety assessment is mandatory for all pediatric formulations. (PAHO)

5. Dosing Principles and Calculations

Weight-Based (mg/kg)

• Standard method for most drugs
• Always cap at maximum adult dose
• Use actual body weight for most drugs; ideal body weight for obese children and certain drugs (aminoglycosides, vancomycin)

Surface Area (mg/m²)

• Preferred for narrow therapeutic index drugs: chemotherapy, methotrexate, cyclosporine, digoxin (for initial dosing)
• BSA = √[(height cm × weight kg) / 3600] (simplified Mosteller formula)
• Prone to measurement error in infants - caution required (PAHO)

Age-Based Dosing Formulas (historical, limited use today)

• Young's Rule: Dose = (Age / Age + 12) × Adult dose (for children > 2 yr)
• Clark's Rule: Dose = (Weight kg / 70) × Adult dose
• These are imprecise; weight- or BSA-based methods are preferred clinically

Dosing in Specific Populations

6. Medication Safety in Pediatrics

• Weight-based dosing calculations - decimal errors (10-fold overdoses are reported)
• Lack of standard formulations - extemporaneous compounding introduces variability
• Multiple strengths of the same drug available - confusion between adult and pediatric concentrations
• Off-label use - majority of drugs used in neonates/infants are not licensed for that age group
• Polypharmacy in complex CYSHCN patients

Prevention Strategies

• Use of standardized concentration lists (e.g., 1 mg/mL standard concentration for high-alert drugs)
• Electronic prescribing with weight-based dose alerts
• Pharmacist medication reconciliation at every care transition
• Double-check systems for high-alert drugs (insulin, opioids, electrolytes)
• Emergency Information Forms (EIFs) for CYSHCN listing all medications, concentrations, and devices (Rosen's Emergency Medicine)
• Parent/caregiver education on correct measuring tools (oral syringes, not household spoons)

7. Off-Label and Unlicensed Drug Use

• Neonatal intensive care (sedatives, inotropes, antifungals)
• Rare pediatric diseases
• Mental health medications in children

• Pediatric Research Equity Act (PREA) and Best Pharmaceuticals for Children Act (BPCA) in the US
• EU Pediatric Regulation mandating Pediatric Investigation Plans (PIPs)
• WHO Model List of Essential Medicines for Children - provides a benchmark for prioritized pediatric drug development

8. Special Drug Classes Requiring Extra Care in Pediatrics

9. Physiologically Based Pharmacokinetic (PBPK) Modeling

• Incorporate age-related changes in organ size, blood flow, enzyme activity, and protein binding
• Allow simulation across all pediatric age categories
• Are superior to simple allometric scaling for clearance prediction
• Support dose selection before clinical trials in vulnerable neonatal populations

Summary

1. Understand developmental pharmacokinetics - ADME differ at every age group
2. Use weight-based (mg/kg) dosing, BSA for narrow therapeutic index drugs
3. Select age-appropriate formulations - palatability, volume accuracy, and safe excipients
4. Monitor closely - especially for renally and hepatically cleared drugs in neonates
5. Prevent medication errors - standardized concentrations, electronic alerts, double-checks
6. Address off-label use proactively - know when TDM is required
7. Use PBPK modeling for drug development and dose optimization in under-studied age groups